Bfsg LLC Sells 745 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Bfsg LLC trimmed its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 6.8% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 10,170 shares of the company’s stock after selling 745 shares during the quarter. Bfsg LLC’s holdings in Teva Pharmaceutical Industries were worth $224,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the company. Diversify Advisory Services LLC boosted its position in Teva Pharmaceutical Industries by 2.5% during the 4th quarter. Diversify Advisory Services LLC now owns 20,355 shares of the company’s stock valued at $426,000 after acquiring an additional 496 shares in the last quarter. Sanctuary Advisors LLC boosted its position in Teva Pharmaceutical Industries by 1.9% during the 3rd quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company’s stock valued at $601,000 after acquiring an additional 664 shares in the last quarter. Sequoia Financial Advisors LLC boosted its position in shares of Teva Pharmaceutical Industries by 0.7% in the 3rd quarter. Sequoia Financial Advisors LLC now owns 112,380 shares of the company’s stock worth $2,025,000 after purchasing an additional 805 shares in the last quarter. DGS Capital Management LLC boosted its position in shares of Teva Pharmaceutical Industries by 6.8% in the 3rd quarter. DGS Capital Management LLC now owns 13,627 shares of the company’s stock worth $246,000 after purchasing an additional 872 shares in the last quarter. Finally, Smithfield Trust Co boosted its position in shares of Teva Pharmaceutical Industries by 55.7% in the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock worth $50,000 after purchasing an additional 980 shares in the last quarter. 54.05% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Piper Sandler boosted their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday, January 17th. UBS Group dropped their price target on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research report on Thursday, January 30th. StockNews.com cut Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. Finally, Barclays dropped their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research report on Thursday, January 30th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, Teva Pharmaceutical Industries currently has an average rating of “Moderate Buy” and an average target price of $23.57.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE TEVA opened at $16.55 on Wednesday. Teva Pharmaceutical Industries Limited has a twelve month low of $12.51 and a twelve month high of $22.80. The company has a 50 day moving average of $19.93 and a 200 day moving average of $18.50. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. As a group, equities research analysts predict that Teva Pharmaceutical Industries Limited will post 2.62 EPS for the current fiscal year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 286,000 shares of the business’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the completion of the sale, the director now directly owns 695,000 shares in the company, valued at approximately $15,296,950. The trade was a 29.15 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.